Therapeutics

MKC-231

Tools

Back to the Top

Overview

Name: MKC-231
Therapy Type: Small Molecule (timeline)
Target Type: Unknown
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Inactive)
Company: Mitsubishi Tanabe Pharma
Approved for: None

Background

MKC-231 is reported to enhance high-affinity choline uptake (HACU), a rate-limiting step in acetylcholine synthesis (Takashina et al., 2008).

Last Updated: 09 Jan 2014

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

Paper Citations

  1. Takashina K, Bessho T, Mori R, Kawai K, Eguchi J, Saito K. MKC-231, a choline uptake enhancer: (3) Mode of action of MKC-231 in the enhancement of high-affinity choline uptake. J Neural Transm. 2008 Jul;115(7):1037-46. Epub 2008 May 7 PubMed.

Further Reading

No Available Further Reading